Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Universitas Indonesia Faculty of Medicine (FMUI) and the University of Oxford's Eijkman Oxford Clinical Research Unit (EOCRU, embedded with the Eijkman Institute of Molecular Biology, EIMB, and part of the Vietnam/Asia Wellcome research programme) have completed a facility dedicated to the support of the many collaborative clinical research activities between the two universities.

EOCRU team

Hosted by the Department of Parasitology on the FMUI campus in central Jakarta, the Universities of Indonesia and Oxford Clinical Research Laboratory (IOCRL) provides an integrated medium for broader engagement with all of our Indonesian friends and partners in training, education, public engagement, and development of a broader collaborative clinical research agenda in the coming years. The IOCRL facility will be managing three active clinical trials in the coming year:

  • ACT-HIV, assessment of adjunctive dexamethasone therapy for TB meningitis in HIV-infected patients at Cipto Mangungkusomo and Persehabatan Hospitals in Jakarta (Wellcome);
  • INSPECTOR pivotal clinical trial of tafenoquine combined with an artemisinin combination therapy for radical cure of vivax malaria in Indonesian soldiers in East Java (GSK UK, Medicines for Malaria Venture, Geneva, and the Bill & Melinda Gates Foundation);
  • a randomized, double-blind, placebo-controlled trial of live Plasmodium falciparum sporozoite vaccines for prevention of acute P. falciparum and acute and latent Plasmodium vivax malaria in Indonesian soldiers (US Congressionally Directed Medical Research Program & Sanaria Inc., USA).

FMUI faculty members serve as the Principal Investigators of each of these endeavours, along FMUI, EIMB (including EOCRU), Oxford University Clinical Research Unit Viet Nam (OUCRU), and Armed Forces of Indonesia co-investigators and technical staff.

The IOCRL facility, managed by Dr Raph Hamers of Oxford University (Centre for Tropical Medicine & Global Health), serves as the administrative, regulatory, and technical hub for these complex and ambitious trials. This remarkably productive engagement of Oxford University with EIMB and FMUI approaches its tenth year with a sense of deep gratitude to these hosts for their warm Indonesian hospitality, collegiality, friendship, and professionalism.

Similar stories

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

@Oxford Research

Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19. Recruitment to the convalescent plasma arm of the RECOVERY trial has now closed. The preliminary analysis based on 1873 reported deaths among 10,406 randomised patients shows no significant difference in the primary endpoint of 28-day mortality. Recruitment to all other treatment arms – tocilizumab, aspirin, colchicine, and Regeneron’s antibody cocktail – continues as planned.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

@Oxford MORU Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

Pearl Gan, OUCRU Photographer in Residence, selected for the Lancet Highlights 2020

OUCRU

Congratulations to Pearl Gan, OUCRU Photographer in Residence, for her winning image selected for the Lancet Highlights 2020: Framing Health Stories. Despite the difficulties of this pandemic year, The Lancet received fascinating and varied entries for our Highlights 2020 photography competition. 15 striking photographs were selected. Each picture captures a unique moment, highlighting a health story.

Receiving and responding to community feedback during health system crises in Kenya

KWTRP Publication Research

The responsiveness of a health system is one of its goals, alongside fairness in financing and outcomes. Listening and responding to the public can make a health system stronger and fairer. However, responsiveness is likely to be undermined, especially for vulnerable and marginal populations, in periods of crises such as disease outbreaks. In the current COVID-19 crisis, there has been more focus on health system control interventions, with minimal consideration of community views. KWTRP colleagues in Kenya consider community engagement and citizens feedback channels, concerns raised by the public and how they were handled, and highlight lessons learned.

RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19

@Oxford Research

Established in March 2020, the RECOVERY trial tests a range of potential treatments for COVID-19, including azithromycin, a widely used antibiotic that also reduces inflammation. The azithromycin arm of the trial was established to determine whether or not the drug has a meaningful benefit among patients hospitalised with COVID-19. A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality; there was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

@Oxford MORU Publication Research

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.